Open Access<p>A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity</p>
Author(s) -
Sang Hee Park,
Xue Han,
Francis Lobo,
Sakinji,
Dipen Patel
Publication year - 2020
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s263903
Subject(s) - abatacept , medicine , adalimumab , rheumatoid arthritis , immunology , antibody , rituximab
The primary objective of this study was to compare the cost per responder (CPR) between abatacept and adalimumab among seropositive rheumatoid arthritis (RA) patients.